Pfizer has received approval from the Subject Expert Committee (SEC) under the Central Drug Standard Control Organisation (CDSCO) to import its 20-Valent Pneumococcal Conjugate Vaccine (20vPnC) into India.
The decision was made following Pfizer’s presentation of global immunogenicity data alongside immunogenicity data specific to Indian subjects. The company also provided comparative data on its 13-valent Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed) I.P.
As reported by medicaldialogues, the 20-valent pneumococcal conjugate vaccine is designed to provide active immunization against infections caused by Streptococcus pneumoniae. Pneumococcal bacteria are a leading cause of pneumonia, as well as other illnesses collectively known as pneumococcal diseases, which include meningitis and bloodstream infections. This vaccine aims to expand protection against pneumococcal disease by targeting 20 serotypes of the bacteria.
At the SEC meeting held on November 26, 2024, experts reviewed and deliberated on the immunogenicity data presented. Based on the evidence provided, the panel recommended granting Pfizer permission to import the vaccine into India. This move is expected to enhance the country’s arsenal in preventing pneumococcal infections and related illnesses.